After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will continue.

Ocugen Inc. closed 73.92% short of its 52-week high of $2.11, which the company reached on March 25th.

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Gyre Therapeutics (GYRE – Research Report), with a ...

Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

Ocugen Inc. closed 75.47% below its 52-week high of $2.11, which the company reached on March 25th.

Ocugen (OCGN) announced that the Data and Safety Monitoring Board for the OCU200 clinical trial recently convened and reviewed safety data ...

The "Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies, RNAi-Based Therapeutics), Application (Diabetes, Cancer), Dosage Form, ...